NASDAQ:GALT - Galectin Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 315.43 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.37
▼ -0.1 (-2.88%)

This chart shows the closing price for GALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galectin Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GALT

Analyst Price Target is $14.00
▲ +315.43% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galectin Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 315.43% upside from the last price of $3.37.

This chart shows the closing price for GALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Galectin Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2021HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00Low
8/13/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $12.00High
4/3/2020B. RileyReiterated RatingBuy$8.00 ➝ $4.00Medium
3/17/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $9.00High
3/7/2019B. RileyInitiated CoverageBuy$11.00Medium
2/13/2019B. RileyInitiated CoverageBuy ➝ Buy$11.00 ➝ $11.00High
8/16/2018HC WainwrightReiterated RatingBuy$12.00Low
5/15/2018HC WainwrightBoost Price TargetBuy$12.00High
1/4/2018Roth CapitalBoost Price TargetBuy$3.00 ➝ $8.00Medium
12/7/2017Roth CapitalLower Price TargetBuy$10.00 ➝ $3.00High
12/7/2017HC WainwrightReiterated RatingBuy$6.00 ➝ $10.00High
11/28/2017HC WainwrightBoost Price TargetBuy$3.50 ➝ $6.00High
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$8.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/A
4/3/2017FBR & Co.Reiterated RatingMarket Perform$2.00Medium
3/30/2017HC WainwrightUpgradeNeutral ➝ Buy$3.50High
2/6/2017FBR & Co.Reiterated RatingMarket Perform$2.00N/A
11/14/2016FBR & Co.Set Price TargetHold$2.00N/A
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
7/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Galectin Therapeutics logo
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Read More

Today's Range

Now: $3.37
Low: $3.35
High: $3.50

50 Day Range

MA: $3.69
Low: $3.28
High: $4.15

52 Week Range

Now: $3.37
Low: $1.82
High: $5.70

Volume

154,300 shs

Average Volume

1,663,870 shs

Market Capitalization

$199.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Galectin Therapeutics?

The following equities research analysts have issued reports on Galectin Therapeutics in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for GALT.

What is the current price target for Galectin Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Galectin Therapeutics in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 315.4%. HC Wainwright has the highest price target set, predicting GALT will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Galectin Therapeutics in the next year.
View the latest price targets for GALT.

What is the current consensus analyst rating for Galectin Therapeutics?

Galectin Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GALT will outperform the market and that investors should add to their positions of Galectin Therapeutics.
View the latest ratings for GALT.

How do I contact Galectin Therapeutics' investor relations team?

Galectin Therapeutics' physical mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company's listed phone number is (678) 620-3186 and its investor relations email address is [email protected] The official website for Galectin Therapeutics is www.galectintherapeutics.com.